Pharmacogenetic Association of the NPPA T2238C Genetic Variant With Cardiovascular Disease Outcomes in Patients With Hypertension

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Yearbook of Cardiology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0145-4145(08)79409-7
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension.

  2008cited by this paper
• Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials.

  2008cited by this paper
• Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study.

  2008cited by this paper
• Surprises of the genome and "personalized" medicine.

  2008cited by this paper
• A kinesin family member 6 variant is associated with coronary heart disease in the Women's Health Study.

  2008cited by this paper
• Natriuretic peptide Val7Met substitution and risk of coronary artery disease in Greek patients with familial hypercholesterolemia

  2006cited by this paper
• Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension.

  2006cited by this paper
• Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension

  1995cited by this paper
• Hypotension in transgenic mice expressing atrial natriuretic factor fusion genes.

  1990cited by this paper

• Efficacy of Immediate Antihypertensive Treatment in Patients With Acute Ischemic Stroke With Different Blood Pressure Genetic Variants

  2024influential citation
• Association of Antihypertensive Drug-Related Gene Polymorphisms with Stroke in the Chinese Hypertensive Population

  2024cites this paper
• Calcium‐channel blockers: Clinical outcome associations with reported pharmacogenetics variants in 32 000 patients

  2022cites this paper
• The T2238C Human Atrial Natriuretic Peptide Molecular Variant and the Risk of Cardiovascular Diseases

  2018influential citation
• Multi-aspect approach to the optimization of pharmacotherapy of patients with arterial hypertension of high and very high risk

  2018cites this paper
• First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.

  2018cites this paper
• Clinical Applications of Personalized Medicine: A New Paradigm and Challenge.

  2017cites this paper
• Cardiovascular pharmacogenetics: a promise for genomically‐guided therapy and personalized medicine

  2017influential citation
• 10 Pharmacogenetics of Essential Hypertension

  2017cites this paper
• Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)

  2017cites this paper
• MOLECULAR PHYSIOLOGY OF MEMBRANE GUANYLYL CYCLASE RECEPTORS

  2016cites this paper
• Hypertension pharmacogenomics: in search of personalized treatment approaches

  2016cites this paper
• T2238C ANP gene variant and risk of recurrent acute coronary syndromes in an Italian cohort of ischemic heart disease patients

  2016cites this paper
• Interventional procedures and future drug therapy for hypertension

  2016cites this paper
• A study to assess association of α-adducin polymorphism in essential hypertensionand its impact on responsiveness to hydrochlorthiazide in patients attending hypertension clinic in a tertiary care hospital.

  2016cites this paper
• Role of the α1 blocker doxazosin in alcoholism: a proof‐of‐concept randomized controlled trial

  2016cites this paper
• Atrial natriuretic peptide in cardiovascular biology and disease (NPPA).

  2015cites this paper
• Associations Between Genetic Variants of the Natriuretic Peptide System and Blood Pressure Response to Dietary Sodium Intervention: The GenSalt Study.

  2015cites this paper
• Natriuretic peptides in cardiovascular diseases: current use and perspectives.

  2014cites this paper
• Cardiovascular Risk Genes in Prevention and Treatment Response

  2014cites this paper
• A Functional Genetic Variant (N521D) in Natriuretic Peptide Receptor 3 Is Associated with Diastolic Dysfunction: The Prevalence of Asymptomatic Ventricular Dysfunction Study

  2014cites this paper
• Association of natriuretic peptide polymorphisms with left ventricular dysfunction in southern Han Chinese coronary artery disease patients.

  2014influential citation
• Association between the atrial natriuretic peptide rs5065 gene polymorphism and the presence and severity of coronary artery disease in an Iranian population

  2014cites this paper
• A Corin Variant Identified in Hypertensive Patients That Alters Cytoplasmic Tail and Reduces Cell Surface Expression and Activity

  2014cites this paper
• Genetics, Ancestry, and Hypertension: Implications for Targeted Antihypertensive Therapies

  2014cites this paper
• Atrial natriuretic peptide gene variants and circulating levels: implications in cardiovascular diseases.

  2014cites this paper
• Blood pressure and urinary sodium excretion in relation to 16 genetic polymorphisms in the natriuretic peptide system in Chinese.

  2014cites this paper
• Natriuretic Peptide Receptor-3 Gene (NPR3): Nonsynonymous Polymorphism Results in Significant Reduction in Protein Expression Because of Accelerated Degradation

  2013cites this paper
• Atrial Natriuretic Peptide Single Nucleotide Polymorphisms in Patients with Nonfamilial Structural Atrial Fibrillation

  2013cites this paper
• C2238 Atrial Natriuretic Peptide Molecular Variant Is Associated With Endothelial Damage and Dysfunction Through Natriuretic Peptide Receptor C Signaling

  2013cites this paper
• Drug Interactions, Pharmacogenomics and Cardiovascular Complication

  2013cites this paper
• Genetic discoveries in hypertension: steps on the road to therapeutic translation

  2013cites this paper
• Angiotensin II type 1 receptor A1166C gene polymorphism and essential hypertension in Calabar and Uyo cities, Nigeria

  2013cites this paper
• Pharmacogenetic Association of NOS3 Variants with Cardiovascular Disease in Patients with Hypertension: The GenHAT Study

  2012cites this paper
• The role of genetics in pre-eclampsia and potential pharmacogenomic interventions

  2012cites this paper
• Pharmacogenetic implications for eight common blood pressure-associated single-nucleotide polymorphisms

  2012cites this paper
• Pharmacogenetics of Essential Hypertension

  2012cites this paper
• Genetics and Pathophysiology of Essential Hypertension

  2012influential citation
• Potential Association Between Frequent Nonsynonymous Variant of NPPA and Cardioembolic Stroke

  2012cites this paper
• Influence of rs5065 atrial natriuretic peptide gene variant on coronary artery disease.

  2012cites this paper
• Pharmacogenomic approaches to study the effects of antihypertensive drugs

  2012cites this paper
• Gene–environment interactions of selected pharmacogenes in arterial hypertension

  2012cites this paper
• Pharmacogenetic Associations of MMP9 and MMP12 Variants with Cardiovascular Disease in Patients with Hypertension

  2011cites this paper
• Gene-Drug Interaction in Stroke

  2011influential citation
• Recent findings in the genetics of blood pressure and hypertension traits.

  2011cites this paper
• Pharmacogenomics: a perspective of personalized medicine in CHD treatment as a model

  2011cites this paper
• Contributions of the atrial natriuretic peptide gene system to the relationship between pediatric body fat, free fatty acids, and blood pressure

  2010cites this paper
• Genome-Wide Association Studies of Hypertension: Have They Been Fruitful?

  2010cites this paper
• Progress toward genetic tailoring of heart failure therapy.

  2010cites this paper
• The genetics of loop diuretic effects

  2010cites this paper
• Forewarned is forearmed: arm with HIF activation.

  2010cites this paper
• Promoter Polymorphism of RGS2 Gene Is Associated with Change of Blood Pressure in Subjects with Antihypertensive Treatment: The Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes Study

  2010cites this paper
• Association of common variants in NPPA and NPPB with blood pressure does not translate into kidney damage in a general population study

  2010cites this paper
• Natriuretic peptide pharmacogenetics: membrane metallo-endopeptidase (MME): common gene sequence variation, functional characterization and degradation.

  2010cites this paper
• Dissecting the genetics of complex traits: lessons from hypertension.

  2010cites this paper
• Determinants of N-terminal proatrial natriuretic peptide plasma levels in a survey of adult male population from Southern Italy

  2010cites this paper
• New and emerging biomarkers of heart failure

  2009cites this paper
• Pharmacogenetics of antihypertensive treatment: detailing disciplinary dissonance.

  2009cites this paper
• Reactive oxygen species-mediated effects on vascular remodeling induced by human atrial natriuretic peptide T2238C molecular variant in endothelial cells in vitro

  2009cites this paper
• Pharmacogenetics and Stroke

  2009cites this paper
• Has pharmacogenetics brought us closer to ‘personalized medicine’ for initial drug treatment of hypertension?

  2009cites this paper
• Pharmacogenetics and Stroke

  2009cites this paper
• Pharmacogenomics in cardiovascular disorders: Steps in approaching personalized medicine in cardiovascular medicine

  2009influential citation
• Genetic polymorphisms of the natriuretic peptide system in the pathogenesis of cardiovascular disease: what lies on the horizon?

  2009cites this paper
• Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases.

  2008cites this paper